Physician profile
Jonathan E Pasko
NPI 1962452904
$1,059.94
in general payments reported to CMS, 2019-2025
20 companies · $62.78 in 2025
The $62.78 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $73.86 · 2021: $122 · 2022: $317 · 2023: $208 · 2024: $44.61 · 2025: $62.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $315.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $176.07 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $116.67 | 2019-2022 | |
| Novo Nordisk INC | $91.23 | 2019-2021 | |
| Glaxosmithkline, LLC. | $82.19 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $76.99 | 2021-2023 | |
| Hologic Sales and Service, LLC | $74.70 | 2023-2024 | Acessa Provu System |
| Lilly USA, LLC | $70.37 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi Pasteur INC. | $65.99 | 2021-2023 | |
| Amgen INC. | $55.92 | 2022-2023 | Evenity, Prolia |
| Exact Sciences Corporation | $42.35 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $40.00 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $34.89 | 2023-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Genentech USA, INC. | $29.28 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $17.18 | 2022 | |
| Biogen, INC. | $16.95 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $15.66 | 2025 | |
| Daiichi Sankyo INC. | $15.35 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.46 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.28 | 2022 | |
| Phadia US INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Pasko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.